Skip to Content
Get key facts and figures about chronic dry eye

Verteporfin Pregnancy and Breastfeeding Warnings

Verteporfin is also known as: Visudyne

Medically reviewed on July 17, 2017.

Verteporfin Pregnancy Warnings

Verteporfin has been assigned to pregnancy category C by the FDA. Animal studies have demonstrated anophthalmia and microphthalmia with high doses. There are no controlled data in human pregnancy. Verteporfin is only recommended for use during pregnancy when benefit outweighs risk.

See references

Verteporfin Breastfeeding Warnings

Verteporfin is excreted into human milk. The effects in the nursing infant are unknown. Because of the potential for serious adverse reactions in nursing infants from verteporfin, a decision should be made whether to discontinue nursing or postpone treatment, taking into account the importance of the drug to the mother.

Verteporfin and its diacid metabolite have been found human breast milk after a 6 mg/m2 infusion. The verteporfin breast milk levels were up to 66% of the corresponding plasma levels and declined below the limit of quantification (2 ng/mL) within 24 hours. The diacid metabolite had lower peak concentrations but persisted up to at least 48 hours.

See references

References for pregnancy information

  1. "Product Information. Visudyne (verteporfin)" Ciba Vision Ophthalmics, Duluth, GA.

References for breastfeeding information

  1. "Product Information. Visudyne (verteporfin)" Ciba Vision Ophthalmics, Duluth, GA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.